Detalhe da pesquisa
1.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature
; 603(7903): 934-941, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130560
2.
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.
Blood
; 137(17): 2321-2325, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512414
3.
Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia.
Pediatr Blood Cancer
; 68(3): e28870, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355997
4.
Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
Curr Oncol Rep
; 22(2): 11, 2020 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31997022
5.
Supercharging your CAR.
Blood
; 135(9): 593-594, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32106308
6.
Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic.
Pediatr Blood Cancer
; 67(9): e28427, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32588960
7.
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Transplant Cell Ther
; 30(2): 155-170, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37863355
8.
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Leukemia
; 38(5): 963-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491306
9.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Cancer Cell
; 42(1): 35-51.e8, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134936
10.
Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849202
11.
Tumor inflammation-associated neurotoxicity.
Nat Med
; 29(4): 803-810, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37024595
12.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Nat Med
; 27(8): 1419-1431, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34312556
13.
Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression.
Mol Cell Biol
; 27(7): 2486-98, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17261592
14.
Prospects and challenges for use of CAR T cell therapies in solid tumors.
Expert Opin Biol Ther
; 20(5): 503-516, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125191
15.
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
J Immunother Cancer
; 8(2)2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929049
16.
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
Clin Cancer Res
; 25(17): 5329-5341, 2019 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31110075
17.
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.
Cancer Res
; 66(4): 2153-61, 2006 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16489016
18.
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
Mol Ther Oncolytics
; 11: 127-137, 2018 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30581986
19.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Nat Med
; 24(1): 20-28, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29155426
20.
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Cancer Immunol Res
; 4(10): 869-880, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27549124